Oramed Pharmaceuticals Inc (ORMP)

$2.6

+0.06

(+2.36%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $2.55
    $2.61
    $2.60
    downward going graph

    1.92%

    Downside

    Day's Volatility :2.3%

    Upside

    0.38%

    downward going graph
  • $1.67
    $3.67
    $2.60
    downward going graph

    35.77%

    Downside

    52 Weeks Volatility :54.5%

    Upside

    29.16%

    downward going graph

Returns

PeriodOramed Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
3.25%
6.5%
0.0%
6 Months
9.48%
7.1%
0.0%
1 Year
-17.53%
9.8%
0.0%
3 Years
-84.11%
14.2%
-20.2%

Highlights

Market Capitalization
104.6M
Book Value
$4.11
Earnings Per Share (EPS)
0.26
PE Ratio
9.77
PEG Ratio
0.0
Wall Street Target Price
3.25
Profit Margin
1551.34%
Operating Margin TTM
-2006.38%
Return On Assets TTM
-4.65%
Return On Equity TTM
6.48%
Revenue TTM
674.0K
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
2.7M
EBITDA
-13.3M
Diluted Eps TTM
0.26
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.01
EPS Estimate Next Year
-0.33
EPS Estimate Current Quarter
0.02
EPS Estimate Next Quarter
-0.02

Analyst Recommendation

Hold
    0
    0%Buy
    57%Hold
    42%Sell
Based on 7 Wall street analysts offering stock ratings for Oramed Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
4
4
4
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 25.0%

Current $2.60
Target $3.25

Technicals Summary

Sell

Neutral

Buy

Oramed Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc
-1.17%
9.48%
-17.53%
-84.11%
-78.23%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc
9.77
9.77
0.0
-0.01
0.06
-0.05
NA
4.11
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc
Hold
$104.6M
-78.23%
9.77
1551.34%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Oramed Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 666.0K → 674.0K (in $), with an average increase of 0.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 13.33M → 1.53M (in $), with an average decrease of 44.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 79.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 270.6%

Institutional Holdings

  • Murchinson Ltd.

    3.40%

  • BML Capital Management LLC

    2.08%

  • BOOTHBAY FUND MANAGEMENT, LLC

    1.70%

  • Susquehanna International Group, LLP

    0.85%

  • Rathbone Brothers PLC

    0.71%

  • Bank of America Corp

    0.71%

Company Information

oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg

Organization
Oramed Pharmaceuticals Inc
Employees
0
CEO
Mr. Nadav Kidron Esq.
Industry
Health Technology

Discover More

FAQs